Binimetinib

CAT#: H 205531

CAS#: 606143-89-9

Description: Binimetinib, also known as MEK162 (ARRY-162), is an oral, highly selective MEK inhibitor. In preclinical studies, MEK162 showed significant antitumor activities in cell lines and animal models. MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.

img

Synthetic Routes

Binimetinib - Synthetic Route 1

Binimetinib route01

Synthetic reference

Anon. Process for the preparation of 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benz[d]imidazole-6-carboxylic acid. IP.com Journal. Volume 15. Issue 12B. Pages 1pp.Journal; Patent. (2015).

Binimetinib - Synthetic Route 2

Binimetinib route02

Synthetic reference

Chen, Jian. Synthetic method of Binimetinib. Assignee Hunan Ouya Biological Co., Ltd., Peop. Rep. China. CN 105820124. (2016).

Binimetinib - Synthetic Route 3

Binimetinib route03

Synthetic reference

Huang, Xizhong; Peters, Malte; Schumacher, Karl Maria; Cao, Zhu Alexander; Gansert, Jennifer Lorraine; Chang, David Dong Eun; Beltran, Pedro. Combination therapy. Assignee Novartis Pharma AG, Switz.; Amgen Inc. WO 2013142182. (2013).

Binimetinib - Synthetic Route 4

Binimetinib route04

Synthetic reference

Wallace, Eli M.; Lyssikatos, Joseph P.; Marlow, Allison L.; Hurley, T. Brian; Koch, Kevin. Preparation of phenylaminobenzimidazolecarboxylates as mitogen activated protein kinase kinase (MEK) inhibitors. Assignee Array BioPharma, Inc., USA. US 20040116710. (2004).